Open AccessThe bioavailability of cytarabine in dogs with meningoencephalitis of unknown etiology through iontophoresis and rectal delivery
Author(s) -
Shelby L. Mancini,
Peter J Early,
Bethany O. Pastina,
Natasha Olby,
Christopher Mariani,
Karen R. Muñana
Publication year - 2021
Publication title -
open veterinary journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.39
H-Index - 10
eISSN - 2226-4485
pISSN - 2218-6050
DOI - 10.4314/ovj.v11i1.6
Subject(s) - iontophoresis , transdermal , rectal administration , medicine , bioavailability , anesthesia , route of administration , pharmacology , radiology
Background: Cytarabine (CA) is used to treat dogs with meningoencephalitis of unknown etiology (MUE) by subcutaneous or intravenous administration.
Aim: The objective was to investigate transdermal iontophoresis and rectal administration as alternative routes of CA delivery.
Methods: Two client-owned dogs with MUE were studied. The ActivaPatch® IONTOGOTM 12.0 iontophoresis drug delivery system delivered 200 mg/m2 CA transdermally. Blood samples were collected by sparse sampling technique after initiation of the device. At another visit, 100 mg/m2 CA was administered rectally. Blood samples were collected by sparse sampling technique after administration. Plasma CA concentrations were measured by high-pressure liquid chromatography.
Results: The concentration of plasma CA after transdermal and rectal administration was below the limits of quantification (0.1 μg/ml) in all samples suggesting inadequate bioavailability with transdermal and rectal administration.
Conclusion: Transdermal and rectal CA administration are not reasonable alternative routes of delivery.